- LegitScript Certified
- US-licensed pharmacy
- Ships in 3 to 5 days
Common questions
PT-141 (Bremelanotide)
Your desire pathway, not your blood flow.
PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use for other purposes is off-label and not FDA-approved. Your provider reviews your file and confirms whether it's clinically appropriate for you.
- Acts on desire, not blood flow
- Use about 45 minutes before
- Subcutaneous injection
- Provider reviewed, real pricing up front
Purchase type
Save 10% today and on every refill. Auto-renews at your selected cadence, pause or cancel anytime.
Cadence
Strength set by your provider. They confirm the right strength and dose after reviewing your required post-purchase intake.
Payment does not guarantee a prescription. Complete the required pharmacist intake after purchase.
What's included
- ✓Medication and supplies
- ✓Provider visit and unlimited follow-ups
- ✓Free expedited shipping
- ✓Injection home kit included
Pause, change, or cancel anytime from your account.
This medication is prepared by a licensed compounding pharmacy. Compounded medications are not reviewed by the FDA for safety or effectiveness and are dispensed only after a licensed provider determines they are appropriate for you.
After checkout you complete a short medical review in your member portal, and a US-licensed provider reviews it before your PT-141 ships.
Works on desire, not blood flow
Bremelanotide acts on melanocortin receptors in the brain that are involved in sexual desire, a different pathway from blood-flow medications.
FDA approved for a specific group
Bremelanotide is FDA approved as Vyleesi for premenopausal women with acquired, generalized HSDD. Any other use is off-label and compounded by a US-licensed pharmacy.
Use it around 45 minutes before
You give a small subcutaneous injection about 45 minutes before intimacy, not on a daily schedule.
Can be paired with other options
Because it works on a different pathway, a provider may combine it with a blood-flow medication when appropriate for you.
About PT-141 (Bremelanotide)
Your provider will explain PT-141 in terms of where it acts, not what it does to blood flow. Bremelanotide, the active compound, is an alpha-MSH analog that activates MC3R and MC4R receptors in your hypothalamus, part of the desire and arousal circuitry your brain runs through dopamine and oxytocin. It works nothing like a PDE5 inhibitor: no vascular effect, no spontaneous arousal created from nothing. You still need arousal cues present for it to do anything. Because the mechanisms don't overlap, some patients are prescribed PT-141 alongside a PDE5 inhibitor rather than as a substitute for one, on your provider's guidance.
- FDA-approved for premenopausal women with HSDD; your provider confirms where your use fits before prescribing
- Acts on your brain's desire pathway through melanocortin receptors, not on blood flow
- In the RECONNECT trials, about 40 percent of women reported meaningful improvement, versus roughly 20 percent on placebo
- Your provider can pair it with a PDE5 inhibitor, since the two mechanisms run separately
You inject a small dose
A subcutaneous injection is given about 45 minutes before intimacy.
It activates melanocortin receptors
Bremelanotide stimulates melanocortin receptors in the hypothalamus, part of the brain's desire circuitry.
Desire signaling is engaged
This pathway is separate from the blood-flow mechanism that PDE5 medicines use.
Bremelanotide engages the brain pathways tied to sexual desire. It does not act on blood flow, so it works differently from ED pills.
How to get it
Today
Answer a few health questions
Share your history, including blood pressure and heart health, in a short intake.
Next
A provider reviews
A US-licensed provider reviews your intake and decides whether bremelanotide is right for you.
3 to 5 days
The pharmacy compounds and ships
If approved, a US-licensed pharmacy prepares your injection and ships it discreetly in 3 to 5 days.
Ongoing
Adjust with follow-ups
Message your care team any time. Your provider can adjust timing or dose based on how you respond and tolerate it.
What the research shows
Bremelanotide is the active ingredient in Vyleesi, which the FDA approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its evidence base comes from the two randomized, placebo-controlled RECONNECT phase 3 trials. Use outside that approved group is off-label.
+0.35
Across the two RECONNECT phase 3 trials, bremelanotide increased the FSFI sexual-desire score versus placebo in premenopausal women with HSDD, an integrated change of 0.35 points (P<.001).
Kingsberg et al., Obstet Gynecol 2019
Less distress
In the same trials, bremelanotide reduced desire-related distress on the FSDS-DAO versus placebo, an integrated change of 0.33 points (P<.001).
Kingsberg et al., Obstet Gynecol 2019
52 weeks
In a 52-week open-label extension, no new safety signals were seen. The most common side effect was nausea, reported by about 40 percent of participants.
Simon et al., Obstet Gynecol 2019
PT-141 (bremelanotide) or PDE5 pills like sildenafil
Two different mechanisms
| PT-141 (bremelanotide) | PDE5 pills like sildenafil | |
|---|---|---|
| How it works | Acts on desire pathways in the brain | Increases blood flow in the body |
| What it targets | Low desire and arousal | Physical erection and blood flow |
| Format | Subcutaneous injection | Oral tablet |
| When you use it | About 45 minutes before | About 30 to 60 minutes before |
| Regulatory status | FDA-approved for premenopausal women with HSDD, off-label otherwise | FDA-approved for erectile dysfunction |
| Can be combined | Yes, on a different pathway | Yes, with provider guidance |
What to expect
PT-141 is typically injected about 45 minutes before anticipated activity, with onset falling between 45 and 90 minutes and a window of effect lasting roughly 4 to 8 hours. The RECONNECT-1 and RECONNECT-2 trials, conducted in premenopausal women with hypoactive sexual desire disorder, found meaningful improvement in about 2 in 5 participants, compared with roughly 1 in 5 on placebo. Roughly 4 in 10 people using PT-141 experience nausea, most commonly in the two hours right after injecting, easing as treatment continues. Headache, a temporary blood pressure increase, injection-site reactions, and flushing round out the commonly reported effects, along with hyperpigmentation, skin, gum, or mole darkening that can develop with repeated use.
- About 45 minutes before
You inject
Give a small subcutaneous injection roughly 45 minutes before intimacy.
- 45 to 90 minutes
It takes effect
Effects on desire typically begin within this window after the injection.
- Up to a few hours
Your window
Effects can last for a few hours. Do not use more than one dose in 24 hours.
- After a few tries
Dial in with your provider
Your provider adjusts timing or dose based on how you respond and how well you tolerate it.
Safety and side effects
PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use for other purposes is off-label and not FDA-approved. This product is compounded by a licensed pharmacy and is not FDA-approved as dispensed. It has not undergone FDA review for safety or efficacy in that compounded form. PT-141 is off the table entirely if your blood pressure runs uncontrolled, or if bremelanotide has ever caused a hypersensitivity response for you. Your provider also factors in any history of cardiovascular disease, reduced liver or kidney function, and whether melanoma runs in your family or your own history, given the theoretical connection between the melanocortin pathway and melanoma risk. Because PT-141 can cause hyperpigmentation, darkening of the skin, gums, or moles, your provider will ask you to keep an eye on your moles and flag any changes.
Common
- Nausea, especially early on
- Flushing
- Headache
- Reaction at the injection site
Less common
- Temporary rise in blood pressure
- Vomiting
- Fatigue
Seek care
- Darkening of the skin or gums with repeated use
- Significant or lasting blood pressure increase
Not for use during pregnancy or when trying to conceive. Not for people with uncontrolled high blood pressure or known cardiovascular disease. Do not use more than one dose in 24 hours or more than eight per month. Tell your provider about all heart and blood pressure conditions. This compounded use is off-label except in premenopausal women with HSDD.
Frequently asked questions
Other sexual health options
Approval is never automatic.
An independent US-licensed clinician reviews every request. If they decide the treatment is not right for you, you get a full refund for the medication.
Prescriptions are filled by a US-licensed pharmacy and shipped free, in discreet packaging, on every plan.
LegitScript-certified · Cert 50087439
Compounded medications are prepared by a US-licensed pharmacy and are not reviewed by the FDA for safety or effectiveness. Products are dispensed only after a licensed provider determines they are appropriate. Information here is educational and is not a substitute for medical advice.